NUCLEOLIN and nasopharyngeal carcinoma: In 2018, Wang and colleagues combined CETSA, molecular docking, and cell-based assay validation and identified nucleolin (NCL) as a target of curcumol that can inhibit the progression of nasopharyngeal carcinoma (Wang J. et al., 2018).